Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
about
Management of relapsed ovarian cancer: a reviewTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsChemotherapy of ovarian cancer in elderly patientsMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentThe role of surgery in advanced epithelial ovarian cancerAntiangiogenic therapies in ovarian cancerBevacizumab in ovarian cancer: A critical review of phase III studiesMajor clinical research advances in gynecologic cancer in 2015Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Audit of CA125 Follow-Up After First-Line Therapy for Ovarian CancerSequential tests for non-proportional hazards data.Same Data; Different InterpretationsOutcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based MedicineNeoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.Ovarian Cancer Incidence Corrected for Oophorectomy.Cytotoxic and Pro-Apoptotic Effects of Cassane Diterpenoids from the Seeds of Caesalpinia sappan in Cancer Cells.BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I studyPrimary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): Mapping probable mechanisms and targets using systems oncologyPlasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survivalPrediction of anti-angiogenesis escape.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.VE-cadherin cleavage by ovarian cancer microparticles induces β-catenin phosphorylation in endothelial cellsPosttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada.Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.SEOM Clinical Guideline in ovarian cancer (2016)LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer.Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B StudyThe Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
P2860
Q26741755-076E4E08-FBC2-4BC0-A0A2-D1FDFC99260BQ26750649-D4DCA94F-AD9E-4405-806E-57AE662ECC61Q26771397-4618DD49-E4E5-4EC8-9611-F33A4522658BQ28066904-A35207A2-A026-4602-8A74-713436C991BCQ28067698-A60384BE-ACD7-47DD-9BEA-98700F6126DBQ28073722-27DE1B96-BEDF-4565-AD9B-6B05F1EA40F1Q28076188-50E3ADC6-32F2-4751-8FDD-E979A1554847Q28077183-01E5A662-0017-477C-BFB0-44DA256B7D1CQ30248296-C49FCF63-0AF3-43D1-8260-7CB966A147F7Q30491211-9E99D617-7B14-432B-A1EA-4F3CD4626C9BQ31057279-A5C21EBA-8103-493F-BCE8-24708FE5D89EQ31125419-6BEF9785-7CB9-4FA5-8016-331954885D18Q33441574-66DEF2B0-2EE2-4B4E-9BFE-8A2602CC8EB7Q33572395-A01E240D-AE38-4605-93F6-F542ECBB06FBQ33626973-BD73CCB8-021E-451E-A095-1F2A91E323B6Q33738954-921EFE4E-6A70-4526-9530-76F6F51E0C52Q33829756-C9CD5466-FB60-40C8-AE0B-CC346CE2A545Q33850454-93EC2A17-C954-4106-85DE-7CA7EA2ABD1DQ36056671-840C81E6-B8C5-4606-8523-E6EA04953873Q36265444-31AA6403-F95D-4339-BE6D-FE0C80434EA2Q36432206-74FFCDFF-7BBD-4C37-B5EC-AEBC3A068E7EQ36546798-C92B1801-4E45-47A1-AC73-FEF7D9938C7EQ36730777-6AA4AD5C-8B65-4CEE-B4AC-27F769B7876CQ36867341-7D45E632-9DEE-4017-B1D0-1121F50C0A41Q36905637-37BB5E67-2403-4746-90FE-0AF83B175878Q36923202-20718D11-EBF1-443D-9E7A-F4A6347FEE80Q37029841-9A96A161-41CC-46AB-93C2-2BAB3A258DCCQ37100738-4131AE83-7499-4116-9C2D-92F1A252AE42Q37289583-0A96E408-D371-4D06-BBAC-1269239E70A8Q37295618-1FC62634-E1D2-4C46-8DA3-C71A58A7D3FCQ37367910-C030A372-9018-4807-931E-47F6E2F5BB81Q37376481-874D61F4-CE7C-458F-854C-CF4F1B32F3BCQ37406889-85565320-6DA9-4F89-BD5E-1E39A08B8CC1Q37475168-DC9A581E-D3F9-4F94-B040-81A7D2CEDD95Q37492937-69130AE4-041E-4784-A59C-1C66D9212AA7Q37529822-1C401669-8B8C-4FA7-9781-91DBA542828FQ37631697-FCF526A9-E16C-4E37-A94A-875B4B73908CQ37654522-7DEFB731-34A2-4B3D-AAD1-F51DEC21831FQ37672829-B6CAEC2D-E9F9-416A-914B-3DD0C429DD6AQ37705894-BB031F8A-F6BF-429C-835B-4A7474E2ACB7
P2860
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@ast
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@en
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@en-gb
type
label
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@ast
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@en
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@en-gb
prefLabel
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@ast
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@en
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@en-gb
P2093
P2860
P50
P921
P1154
2-s2.0-84938198626
P1433
P1476
Standard chemotherapy with or ...... of a phase 3 randomised trial.
@en
P2093
Adrian D Cook
Amit M Oza
Andrés Cervantes
Andrés Poveda
Ann Marie Swart
Gordon Rustin
Gunnar Kristensen
ICON7 trial investigators
Jacobus Pfisterer
Jonathan A Ledermann
P2860
P304
P356
10.1016/S1470-2045(15)00086-8
P5530
P577
2015-06-23T00:00:00Z
P6179
1048975734